^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    enavatuzumab (PDL192)

    i
    Other names: PDL192, ABT-361
    Associations

    News

    Trials
    Company:
    AbbVie
    Drug class:
    TWEAK inhibitor
    Associations

    News

    Trials
    over1year
    Single-cell RNA sequencing and spatial transcriptomics of bladder Ewing sarcoma. (PubMed, iScience)
    In addition, Enavatuzumab can significantly inhibit the migratory ability of the Ewing sarcoma cell line RD-ES. This groundbreaking study provides unprecedented mechanistic insights into the progression of bladder ES/PNET and introduces a potential therapeutic avenue for treating this challenging malignancy.
    Journal
    |
    TNFRSF12A (TNF Receptor Superfamily Member 12A)
    |
    enavatuzumab (PDL192)
    2years
    Non-invasive Measurement of PD-L1 Levels With Positron Emission Tomography (PET) in Head and Neck Malignancies and Intracranial Metastases (clinicaltrials.gov)
    P1, N=7, Terminated, Yale University | N=24 --> 7 | Trial completion date: Jun 2024 --> Jan 2024 | Recruiting --> Terminated | Trial primary completion date: Jun 2024 --> Jan 2024; PI changed institutions
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    enavatuzumab (PDL192)
    over2years
    Antibody-based soluble and membrane-bound TWEAK mimicking agonists with FcγR-independent activity. (PubMed, Front Immunol)
    Noteworthy, activation of the classical NFκB pathway, which naturally is predominately triggered by membrane-bound TWEAK but not soluble TWEAK, was preferentially observed with a subset of constructs containing Fn14 binding sites at opposing sites of the IgG scaffold, e.g. IgG1-scFv fusion proteins. A superior ability of IgG1-scFv fusion proteins to trigger classical NFκB signaling was also observed with the anti-Fn14 antibody PDL192 suggesting that we identified generic structures for Fn14 antibody variants mimicking soluble and membrane-bound TWEAK.
    Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha)
    |
    enavatuzumab (PDL192)
    almost3years
    Non-invasive Measurement of PD-L1 Levels With Positron Emission Tomography (PET) in Head and Neck Malignancies and Intracranial Metastases (clinicaltrials.gov)
    P1, N=24, Recruiting, Yale University | Not yet recruiting --> Recruiting | Initiation date: Nov 2022 --> Feb 2023
    Enrollment open • Trial initiation date
    |
    PD-L1 (Programmed death ligand 1)
    |
    enavatuzumab (PDL192)
    over3years
    Non-invasive Measurement of PD-L1 Levels With Positron Emission Tomography (PET) in Head and Neck Malignancies and Intracranial Metastases (clinicaltrials.gov)
    P1, N=24, Not yet recruiting, Yale University | Initiation date: Aug 2022 --> Nov 2022
    Trial initiation date
    |
    PD-L1 (Programmed death ligand 1)
    |
    enavatuzumab (PDL192)
    over3years
    Non-invasive Measurement of PD-L1 Levels With Positron Emission Tomography (PET) in Head and Neck Malignancies and Intracranial Metastases (clinicaltrials.gov)
    P1, N=24, Not yet recruiting, Yale University
    New P1 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    enavatuzumab (PDL192)